Abstract:, anidulafungin ( AFG ,and combinationsof FLC + AFG,AFG + AMB,andFLC + AMBagainst 17 C.albicans isolates obtained from the oral cavity of cancer patients. Isolates that had not been exposed to antifungals, served as a control group. Colony counts were performed at 0, 2, 4, 6, and 24 h after a brief ( 1 h ) antifungal exposure. Results: The FLC had no detectable post-antifungal effect independent of antifungal concentration and resembled drug-free FLC ( control ) . When all AMB and AFG were compared with FLC, significant variations in the post-antifungal effect were observed. Combining AFG and AMB with FLC resulted in effective activity compared to FLC alone. Combination regimens were rated as indifferent in general. Interestingly, low dosages of the AFG displayed increasing fungistatic action as it neared a fungistatic endpoint against C. albicans isolates ( n = 17 ) . Conclusion: Our findings suggest that brief exposure to AFG, in combination with FLC and AMB, at low concentrations of the medicines utilized, could be effective in the evaluation and optimization of new dosage regimens to manage candidiasis. However, future research will look at the clinical utility of our findings. albicans is the most common cause of nosocomial and are with morbidity and in However, limited therapeutic approaches against invasive candidiasis are available. The rise in antifungal resistance highlights the urgent need to develop new therapeutic options and novel this was an in regard of the showed a significant decrease in the number of loads,similar to the group with ATTAF-1 and ATTAF-2. Nevertheless, the results this study that the use of and ATTAF-2 as a therapeutic agent can exert significant in and in vivo antifungal effects C.albicans ,increasing animal and significantly decreasing loads. Conclusion: Although we have identified two new compounds, ATTAF-1 and ATTAF-2, as novel promising Candidates for the of studies of ATTAF-1 and ATTAF-2 activity and their action mechanisms in animal models are warranted to enhance our understanding and establish their efficacy. Antifungal-resistant dermatophytosis is an emerging threat with cases of chronic,recurrent infection reported from several countriesincluding India. Additionally, the rapidspread of infections involves person-to-personspread.Our results suggest that a clonal outbreak of a T. indotineae strain is circulating in multiple states in India. Current plans are to expand the geographic scope of the study by including over 10 countries from Europe, Middle East, and the Americas. This work will allow the publichealth community to better understandthe emergence and transmissionof antifungal-resistant dermatophytosis worldwide.

Eucalyptal D Enhances the Antifungal Effect of Fluconazole on Fluconazole-Resistant Candida Albicans by Competitively Inhibiting Efflux Pump

Synergistic Effect of the Combination of Deferoxamine and Fluconazole in Vitro and in Vivo Against Fluconazole-Resistant Candida Spp.

Synergistic and drug-resistant reversing effects of diorcinol D combined with fluconazole against Candida albicans.

Synergistic effect of eravacycline combined with fluconazole against resistant Candida albicans in vitro and in vivo

Synergic effect of deferoxamine combined with fluconazole against fluconazole-resistant <i>Candida</i> Spp. through inhibited Cek1 MAPK signaling pathway

Synergistic Effect of Fluconazole and Calcium Channel Blockers against Resistant Candida albicans

Synergistic Antifungal Effect of Fluconazole Combined with Licofelone Against Resistant Candida Albicans

The Efflux Pump Inhibitor Tetrandrine Exhibits Synergism with Fluconazole or Voriconazole Against Candida Parapsilosis

Synergic Effect of Deferoxamine Combined with Fluconazole Against Fluconazole-Resistant Candida Spp. Through Inhibited Cek1 MAPK Signaling Pathway

A mechanism study on the synergistic effects of rifapentine and fluconazole against fluconazole-resistant Candida albicans in vitro

Combination of fluconazole with natural compounds: A promising strategy to manage resistant Candida albicans infections

The Effect of Ginkgolide B Combined with Fluconazole Against Drug-Resistant Candida Albicans Based on Common Resistance Mechanisms

In Vitro Synergism of Fluconazole and Baicalein Against Clinical Isolates of Candida Albicans Resistant to Fluconazole.

Synergistic Antifungal Effect of Glabridin and Fluconazole.

In vitro and in vivo analysis of monotherapy and dual therapy with ethyl caffeate and fluconazole on virulence factors of Candida albicans and systemic candidiasis

Synergistic effect of mangiferin in combination with fluconazole against fluconazole-resistant Candida albicans

Mechanism and bioinformatics analysis of the effect of berberine-enhanced fluconazole against drug-resistant Candida albicans

Ellagic Acid Potentiates the Inhibitory Effects of Fluconazole Against Candida albicans

ABC Transporters Coupled with the Elevated Ergosterol Contents Contribute to the Azole Resistance and Amphotericin B Susceptibility

Proteomic analysis reveals a synergistic mechanism of fluconazole and berberine against fluconazole-resistant Candida albicans: endogenous ROS augmentation.

Fluconazole Assists Berberine to Kill Fluconazole-Resistant Candida Albicans